Peptides in the era of biotech

Advanced Therapy Medicinal Products (ATMPs) are revolutionizing the treatment of a wide range of severe diseases. Their potential to deliver long-lasting or even curative effects places them at the forefront of biomedical innovation. However, despite their clinical promise, the successful development and widespread adoption of ATMPs face two critical hurdles: high manufacturing costs and market access specificities.

Several emerging strategies leveraged by automated labs, aim to improve discovery, efficiency and reliability in designing chemical routes.

High throughput screening (HTS) and experimentation (HTE) are techniques which allow the execution of large numbers of experiments to be conducted in parallel while requiring less effort per experiment when compared to conventional means of experimentation. A reiterative process of design, execution, data analysis, and hit identification enables rapid exploration of conditions for reaction discovery and optimization.